Women with previously untreated advanced disease after surgery were randomly allocated to six cycles of platinum-taxane chemotherapy plus placebo cycles ( C ) @ to C@ ( R@ ) ; chemotherapy plus bevacizumab C@ to C@ plus placebo C@ to C@ ( R@ ) ; or chemotherapy plus bevacizumab C@ to C@ ( R@ ) .